• Title/Summary/Keyword: Anti-asthma

Search Result 245, Processing Time 0.029 seconds

The Association of Asthma and Osteoporosis in the Residents of the Local Community (지역사회 주민을 대상으로 한 천식과 골다공증과의 연관성)

  • Park, Kyung-Yong;Lee, Sok-Goo
    • Journal of agricultural medicine and community health
    • /
    • v.34 no.3
    • /
    • pp.316-323
    • /
    • 2009
  • Objectives: Corticosteroids, usually as an inhaled form, are usually used to treat narrowed airway in the treatment of asthma. However, the use of corticosteroid commonly associated with the development of osteoporosis. In this study, we studied the association of asthma and osteoporosis in the residents of the local community. Methods: As a part of the Local Community Health Study Chungnam 2008, the residents are surveyed with the formal questionnaire. We analyzed the association between asthma and osteoporosis data with the questionnaire. Results: We analyzed total 6,348 data from the residents in Chungnam province. Of them, 203(3.2%) were asthma patients and 465(7.3%) were osteoporosis patients. Patients with asthma have more advanced age(p<0.001), higher incidence of hypertension(p<0.001) and diabetes(p=0.001), lower incidence of exercise(p=0.002) and economic activity(p<0.001). Patients with osteoporosis have more advanced age (p<0.001), female predominance(p<0.001), higher incidence of hypertension (p<0.001), diabetes(p=0.001), and fractures (p<0.001), lower incidence of exercise (p=0.002) and economic activity (p<0.001). In total population, asthma is associated with the increased incidence of osteoporosis, especially in patients treated with anti-asthmatic medications. Conclusions: Through this study, we demonstrated the presence of asthma is closely associated with the increased incidence of osteoporosis, especially in patients treated with anti-asthmatic medications. Therefore, further and broad study will be needed to evaluate the association of asthma and the types of anti-asthmatic medications in the development of osteoporosis.

Immunologic Basis of Type 2 Biologics for Severe Asthma

  • Soyoon Sim;Youngwoo Choi;Hae-Sim Park
    • IMMUNE NETWORK
    • /
    • v.22 no.6
    • /
    • pp.45.1-45.15
    • /
    • 2022
  • Asthma is a chronic airway inflammatory disease characterized by reversible airway obstruction and airway hyperreactivity to various environmental stimuli, leading to recurrent cough, dyspnea, and wheezing episodes. Regarding inflammatory mechanisms, type 2/eosinophilic inflammation along with activated mast cells is the major one; however, diverse mechanisms, including structural cells-derived and non-type 2/neutrophilic inflammations are involved, presenting heterogenous phenotypes. Although most asthmatic patients could be properly controlled by the guided treatment, patients with severe asthma (SA; classified as a treatment-refractory group) suffer from uncontrolled symptoms with frequent asthma exacerbations even on regular anti-inflammatory medications, raising needs for additional controllers, including biologics that target specific molecules found in asthmatic airway, and achieving the precision medicine for asthma. This review summarizes the immunologic basis of airway inflammatory mechanisms and current biologics for SA in order to address unmet needs for future targets.

Effects of Anti-Asthma Agents on Cytokine and Prostaglandin Production in Ovalbumin-Sensitized Splenocytes

  • Won, Tae-Joon;Lee, Chan-Woo;Kwon, Seok-Joong;Lee, Do-Ik;Park, So-Young;Hwang, Kwang-Woo
    • Biomolecules & Therapeutics
    • /
    • v.17 no.4
    • /
    • pp.388-394
    • /
    • 2009
  • The cytokines which is produced by allergen-specific T helper (Th) cells play a pivotal role in the pathogenesis of asthma. Asthma is caused by exaggerated T-helper 2 (Th2)-based immune responses. It is suggested that controlling such Th2-based response is necessary for asthma therapy. The current therapies for asthma focus primarily on control of symptoms and suppression of inflammation, without affecting the underlying cause. So, we examined that anti-asthmatic drugs might have play a certain role in Th2/Th1 balance. Splenocytes isolated from ovalbumin (OVA)-sensitized mice cultured with anti-asthmatic drugs. It is well known that Th2 and Th1 immune responses can balance one another, as Th2 mediators suppress Th1 responses and Th1 mediators similarly inhibit Th2 responses. But salmeterol inhibits both of Th1 and Th2 mediators, which salmeterol is a suppressor of immune responses not only a suppressor of Th2-based immune responses. Aminophylline is a weak suppressor of immune responses. But ipratropium and cromoglycate don't have any suppressor effect to Th2-driven responses. They only have suppressor effect to Th1 immune responses. Salmeterol, ipratropium, aminophylline, and cromoglycate augmented mRNA levels of CRTH2, EP2, and IP2 receptors in OVA-sensitized splenocytes. It is well known that the up-regulation of CRTH2 - $PGD_2$ receptor - results in restraint of eosinophil recruitment and that the increment of IP and EP2 - $PGI_2$ and $PGE_2$ receptor, respectively - may induce the accumulation of cAMP that decrease the effector function of T cells. Moreover salmeterol and cromoglycate increase the mRNA expression of $PGD_2$ synthase. These findings indicate that anti-asthma agents may alleviate the immunological responses that cause the asthmatic diseases.

The Convergence Study on the Effects of White Ginseng Complex Extracts on OVA-induced Allergic Asthma in Mice (백삼복합물이 난알부민으로 유도된 천식 마우스에서의 천식개선에 대한 융복합 연구)

  • Ji, Joong-Gu
    • Journal of Digital Convergence
    • /
    • v.14 no.6
    • /
    • pp.317-323
    • /
    • 2016
  • The aim of the convergence study is to evaluate anti-asthma effects of white ginseng complex extract(WGCE) on OVA-induced allergic asthma in mice. WGCE was administered at 100 mg/kg and 300 mg/kg to mice, where asthma was induced by OVA. Th2 cytokine including IL-4, IL-5 and IL-13 were measured by Luminex. Also, OVA-IgE and eosinophil were measured by haemocytometer and BALF total cells were measured microscope. Production of IL-4, IL-5, IL-13 and OVA-IgE in serum was decreased, respectively, in comparison with control. The eosinophil in whole blood decreased significantly. In addition, WGCE groups showed a decrease in the BALF total cells. These results demonstrated that WGCE decreases the Th2 cytokine and asthma factors. Therefore, we strongly suggest that WGCE could be effectively used as a therapeutic drug based on its anti asthma factors.

Expression of Muscarinic Receptors and the Effect of Tiotropium Bromide in Aged Mouse Model of Chronic Asthma

  • Kang, Ji Young;Kim, In Kyoung;Hur, Jung;Kim, Seok Chan;Lee, Sook Young;Kwon, Soon Seog;Kim, Young Kyoon
    • Tuberculosis and Respiratory Diseases
    • /
    • v.82 no.1
    • /
    • pp.71-80
    • /
    • 2019
  • Background: Efficacy and safety of tiotropium bromide, a muscarinic receptor antagonist, in treatment of asthma have been reported. However, its effect on airway remodeling in chronic asthma of the elderly has not been clearly verified. The objective of this study was to investigate the effect of tiotropium and expression of muscarinic receptors as its related mechanism in an aged mouse model of chronic asthma with airway remodeling. Methods: BALB/c female mice age 6 weeks, 9 and 15 months were sensitized and challenged with ovalbumin (OVA) for three months. Tiotropium bromide was administered during the challenge period. Airway hyperresponsiveness (AHR) and pulmonary inflammation were measured. Parameters of airway remodeling, and expression levels of $M_2$ and $M_3$ receptors were examined. Results: Total cell with eosinophils, increased in the OVA groups by age, was decreased significantly after treatment with tiotropium bromide, particularly in the age group of 15 months. AHR and levels of interleukin (IL)-4, IL-5, and IL-13 were decreased, after tiotropium administration. In old aged group of 9- and 15-months-treated groups, hydroxyproline contents and levels of ${\alpha}$-smooth muscle actin were attenuated. Tiotropium enhanced the expression of $M_2$ but decreased expression of $M_3$ in all aged groups of OVA. Conclusion: Tiotropium bromide had anti-inflammatory and anti-remodeling effects in an aged mouse model of chronic asthma. Its effects seemed to be partly mediated by modulating expression $M_3$ and $M_2$ muscarinic receptors. Tiotropium may be a beneficial treatment option for the elderly with airway remodeling of chronic asthma.

Suppressive Effect of CYM50358 S1P4 Antagonist on Mast Cell Degranulation and Allergic Asthma in Mice

  • Jeon, Wi-Jin;Chung, Ki Wung;Lee, Joon-Hee;Im, Dong-Soon
    • Biomolecules & Therapeutics
    • /
    • v.29 no.5
    • /
    • pp.492-497
    • /
    • 2021
  • Levels of sphingosine 1-phosphate (S1P), an intercellular signaling molecule, reportedly increase in the bronchoalveolar lavage fluids of patients with asthma. Although the type 4 S1P receptor, S1P4 has been detected in mast cells, its functions have been poorly investigated in an allergic asthma model in vivo. S1P4 functions were evaluated following treatment of CYM50358, a selective antagonist of S1P4, in an ovalbumin-induced allergic asthma model, and antigen-induced degranulation of mast cells. CYM50358 inhibited antigen-induced degranulation in RBL-2H3 mast cells. Eosinophil accumulation and an increase of Th2 cytokine levels were measured in the bronchoalveolar lavage fluid and via the inflammation of the lungs in ovalbumin-induced allergic asthma mice. CYM50358 administration before ovalbumin sensitization and before the antigen challenge strongly inhibited the increase of eosinophils and lymphocytes in the bronchoalveolar lavage fluid. CYM50358 administration inhibited the increase of IL-4 cytokines and serum IgE levels. Histological studies revealed that CYM50358 reduced inflammatory scores and PAS (periodic acid-Schiff)-stained cells in the lungs. The pro-allergic functions of S1P4 were elucidated using in vitro mast cells and in vivo ovalbumin-induced allergic asthma model experiments. These results suggest that S1P4 antagonist CYM50358 may have therapeutic potential in the treatment of allergic asthma.

The Effects of Gamchomahwang-tang extract According to the ratio of 2 compounds on the Ovalbumin-Induced Allergic Asthma in Mice (甘草麻黃湯 추출물의 배합 비율에 따른 투여가 Ovalbumin으로 유발된 천식 생쥐에 미치는 영향)

  • Jo, So-Hyun;Jo, Eun-Hee;Park, Min-Cheol
    • The Journal of Korean Medicine Ophthalmology and Otolaryngology and Dermatology
    • /
    • v.28 no.4
    • /
    • pp.74-91
    • /
    • 2015
  • Background and Objective : Asthma is a chronic inflammatory disease at the mucosa and is associated with excess production of Th2 cytokine and eosinophil accumulation in lung.Gamchomahwang-tangextract(GME) is one of the well known prescription used in oriental medicine for treating asthma. This study was designed to compare the anti-asthmatic effect of GME according to the ratio of 2 compounds.Methods : To examine the effects of GME on asthma, mice were sensitized with 100 ㎍ of OVA and 1 ㎎ of aluminum potassium sulfate(Alum; Sigma) intraperitoneally on day 1 and 15. From day 22, mice were challenged on 3 consecutive days with 5% OVA. The anti-asthmatic effects of GME were evaluated by enhanced pause(Penh), bronchoalveolar lavage fluids (BALF), inflammatory cytokine production and genes expression, serum IgE production. and histological change in lung tissue. GMEⅠ consists of ES and GU in the proportion 2:1(300 ㎎/㎏ group), GMEⅡ consist of ES and GU in the proprtion 4:1(300 ㎎/㎏ group).Results : GMEⅠ,Ⅱ generally inhibited lung inflammation, inflammatory cells infiltration and cytokine production and gene expression such as IL-4, IL-5 and IL-13 in BALF and serum IgE level. GMEⅡ significantly reduced the cytokine production and gene expression such as IL-4, IL-5 and IL-13 in BALF and GMEⅠ decreased cytokine production of IL-4, IL-13 in BALF and gene expression of IL-4, IL-5 in Lung. GMEⅡ potently inhibited the development of Penh and also reduced the number of eosinophil during OVA-induced AHR(airway hyper-reactivity). Overall the results show that GMEⅡ has more effect on inhibiting production, gene expression of cytokine, serum IgE level and development of Penh than GMEⅠ. Consequently, GMEⅡ might be more effective than GMEⅠ at inhibiting allergic asthma on the OVA-induced mice model.Conclusion : These results indicate that GME has a deep inhibitory effects on airway inflammation and hyperresponsiveness in mice model of asthma and that suppression of IL-4, IL-5, IL-13 expression and decrease of IL-4, IL-5, IL-13 production in BALF might contribute this effect. Hence, the results indicate that GME might be useful herbal medicine of allergic asthma. As a result, GMEⅡ mght be superior to GMEⅠ in the aspect of anti-asthmatic effect on the OVA-induced mice model.

Korean Red Ginseng affects ovalbumin-induced asthma by modulating IL-12, IL-4, and IL-6 levels and the NF-κB/COX-2 and PGE2 pathways

  • Lee, Soon-Young;Kim, Min-Hee;Kim, Seung-Hyun;Ahn, Taeho;Kim, Sung-Won;Kwak, Yi-Seong;Cho, Ik-Hyun;Nah, Seung-Yeol;Cho, Seung-Sik;Park, Kyung Mok;Park, Dae-Hun;Bae, Chun-Sik
    • Journal of Ginseng Research
    • /
    • v.45 no.4
    • /
    • pp.482-489
    • /
    • 2021
  • Background: Asthma is an incurable hyper-responsive disease of the pulmonary system that is caused by various allergens, including indoor and outdoor stimulators. According to the Global Asthma Network, 339 million people suffered from asthma in 2018, with particularly severe forms in children. Numerous treatments for asthma are available; however, they are frequently associated with adverse effects such as growth retardation, neurological disorders (e.g., catatonia, poor concentration, and insomnia), and physiological disorders (e.g., immunosuppression, hypertension, hyperglycemia, and osteoporosis). Methods: Korean Red Ginseng has long been used to treat numerous diseases in many countries, and we investigated the anti-asthmatic effects and mechanisms of action of Korean Red Ginseng. Eighty-four BALB/c mice were assigned to 6 treatment groups: control, ovalbumin-induced asthma group, dexamethasone treatment group, and 3 groups treated with Korean Red Ginseng water extract (KRGWE) at 5, 25, or 50 mg/kg/day for 5 days. Anti-asthmatic effects of KRGWE were assessed based on biological changes, such as white blood cell counts and differential counts in the bronchoalveolar lavage fluid, serum IgE levels, and histopathological changes in the lungs, and by examining anti-asthmatic mechanisms, such as the cytokines associated with Th1, Th2, and Treg cells and inflammation pathways. Results: KRGWE affected ovalbumin-induced changes, such as increased white blood cell counts, increased IgE levels, and morphological changes (mucous hypersecretion, epithelial cell hyperplasia, inflammatory cell infiltration) by downregulating cytokines such as IL-12, IL-4, and IL-6 via GATA-3 inactivation and suppression of inflammation via NF-κB/COX-2 and PGE2 pathways. Conclusion: KRGWE is a promising drug for asthma treatment.

Cost-of-illness Study of Asthma in Korea: Estimated from the Korea National Health Insurance Claims Database (건강보험 청구자료를 이용한 우리나라 천식환자의 질병비용부담 추계)

  • Park, Choon-Seon;Kwon, Il;Kang, Dae-Ryong;Jung, Hye-Young;Kang, Hye-Young
    • Journal of Preventive Medicine and Public Health
    • /
    • v.39 no.5
    • /
    • pp.397-403
    • /
    • 2006
  • Objectives: We estimated the asthma-related health care utilization and costs in Korea from the insurer's and societal perspective. Methods: We extracted the insurance claims records from the Korea National Health Insurance claims database for determining the health care services provided to patients with asthma in 2003. Patients were defined as having asthma if they had ${\geq}$2 medical claims with diagnosis of asthma and they had been prescribed anti-asthma medicines, Annual claims records were aggeregated for each patient to produce patient-specific information on the total utilization and costs. The total asthma-related cost was the sum of the direct healthcare costs, the transportation costs for visits to health care providers and the patient's or caregivers' costs for the time spent on hospital or outpatient visits. Results: A total of 699,603people were identified as asthma patients, yielding an asthma prevalence of 1.47%. Each asthma patient had 7.56 outpatient visits, 0.01 ED visits and 0.02 admissions per year to treat asthma. The per-capita insurance-covered costs increased with age, from 128,276 Won for children aged 1 to 14 years to 270,729 Won for those aged 75 or older. The total cost in the nation varied from 121,865 million to 174,949 million Won depending on the perspectives. From a societal perspective, direct health care costs accounted for 84.9%, transportation costs for 15.1 % and time costs for 9.2% of the total costs. Conclusions: Hospitalizations and ED visits represented only a small portion of the asthma-related costs. Most of the societal burden was attributed to direct medical expenditures, with outpatient visits and medications emerging as the single largest cost components.

A Review of Marine Algae-derived Therapeutic Agents for Respiratory Disease Asthma (해조류 유래 호흡기 질환 천식 치료제 연구 동향)

  • Kim, Tae-Hee;Heo, Seong-Yeong;Oh, Gun-Woo;Kim, Min-Sung;Choi, Il-Whan;Jung, Won-Kyo
    • Journal of Marine Bioscience and Biotechnology
    • /
    • v.12 no.1
    • /
    • pp.1-10
    • /
    • 2020
  • Asthma is a complex inflammatory disease of the lung characterized by variable airflow obstruction, airway hyperresponsiveness, airway inflammation, and reduction of respiratory function. Its prevalence and incidence are increasing because of the effect of various environmental and lifestyle risk factors. Steroid inhalation, long-acting agonists, and other synthetic drugs are used for the treatment of this disease. However, they have some side effects and show unsatisfied result and response after treatment. Therefore, many researchers have focused on the development of natural product-related treatment for asthma to suppress the side effects and unsatisfied results. Seaweeds contain various bioactive compounds with anti-inflammatory, antibacterial, and anti-oxidant activities. Thus, we investigated the asthma treatment-related literature using marine algae via the Google scholar search engine. Consequently, the literature is rarely investigated, but is increasing steadily. The literature was performed as a comparison study with an ovalbumin-induced group or drug-treated group, and investigated the antiasthma activity of algae ethanol extract. Although many researchers have studied marine algae-derived therapeutic agents for asthma, the amount of literature is rare compared with those of herbal medicine-derived therapeutic agents. Conclusively, we suggest that many researchers should investigate and develop algae-derived therapeutic agents for asthma treatment.